These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23881879)

  • 1. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.
    Corazza O; Assi S; Simonato P; Corkery J; Bersani FS; Demetrovics Z; Stair J; Fergus S; Pezzolesi C; Pasinetti M; Deluca P; Drummond C; Davey Z; Blaszko U; Moskalewicz J; Mervo B; Furia LD; Farre M; Flesland L; Pisarska A; Shapiro H; Siemann H; Skutle A; Sferrazza E; Torrens M; Sambola F; van der Kreeft P; Scherbaum N; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):317-23. PubMed ID: 23881879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project.
    Deluca P; Davey Z; Corazza O; Di Furia L; Farre M; Flesland LH; Mannonen M; Majava A; Peltoniemi T; Pasinetti M; Pezzolesi C; Scherbaum N; Siemann H; Skutle A; Torrens M; van der Kreeft P; Iversen E; Schifano F
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):221-6. PubMed ID: 22841965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey.
    Simonato P; Corazza O; Santonastaso P; Corkery J; Deluca P; Davey Z; Blaszko U; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):324-31. PubMed ID: 23881880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenge of complex drug use: Associated use of codeine-containing medicines and new psychoactive substances in a European cross-sectional online population.
    Kimergård A; Foley M; Davey Z; Wadsworth E; Drummond C; Deluca P
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28597537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
    Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel psychoactive substances (NPS) - knowledge and expe riences of drug users from Hungary, Poland, the UK and the USA.
    Pisarska A; Deluca P; Demetrovics Z; Moskalewicz J; ReDNet G
    Neuropsychopharmacol Hung; 2019 Dec; 21(4):152-163. PubMed ID: 32015192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
    Zaami S
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New/emerging psychoactive substances and associated psychopathological consequences.
    Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
    Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
    Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
    Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages.
    Corazza O; Assi S; Malekianragheb S; Beni MN; Bigdeli I; Aslanpour Z; Schifano F
    Int J Drug Policy; 2014 Jul; 25(4):724-6. PubMed ID: 24917190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
    Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
    Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs on the web; the Psychonaut 2002 EU project.
    Schifano F; Deluca P; Baldacchino A; Peltoniemi T; Scherbaum N; Torrens M; Farre M; Flores I; Rossi M; Eastwood D; Guionnet C; Rawaf S; Agosti L; Di Furia L; Brigada R; Majava A; Siemann H; Leoni M; Tomasin A; Rovetto F; Ghodse AH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):640-6. PubMed ID: 16458404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union.
    Varì MR; Mannocchi G; Tittarelli R; Campanozzi LL; Nittari G; Feola A; Umani Ronchi F; Ricci G
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33238595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review.
    Orsolini L; Chiappini S; Corkery JM; Guirguis A; Papanti D; Schifano F
    Expert Rev Neurother; 2019 Dec; 19(12):1253-1264. PubMed ID: 31503507
    [No Abstract]   [Full Text] [Related]  

  • 16. Collaboration of the Joint Research Centre and European Customs Laboratories for the Identification of New Psychoactive Substances.
    Guillou C; Reniero F; Lobo Vicente J; Holland M; Kolar K; Chassaigne H; Tirendi S; Schepers H
    Curr Pharm Biotechnol; 2018; 19(2):91-98. PubMed ID: 29792142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs of abuse on the Web: the role of the Psychonaut Web Mapping Project].
    Schifano F; Ricciardi A; Corazza O; Deluca P; Davey Z; Rafanelli C;
    Riv Psichiatr; 2010; 45(2):88-93. PubMed ID: 20568579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS).
    Deligianni E; Corkery JM; Schifano F; Lione LA
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28485125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
    Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
    PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.